Dupixent use
Whether Dupixent was used before a CTCL-related diagnosis, and the general timing of treatment.
Dupixent CTCL Litigation
About MedLaw Group
MedLaw Group reviews pharmaceutical and medical product injury inquiries, including emerging mass tort and MDL matters. For Dupixent, the current review is focused on CTCL and related T-cell lymphoma diagnoses.
Attorney review with pharmaceutical, biotechnology, and federal litigation experience
Keke Feng, Esq.
Attorney reviewing nationwide Dupixent CTCL inquiries for MedLaw Group.
- Admitted in the State Court of California
- Admitted in the United States District Court, Northern District of California
- Former biopharma legal executive with pharmaceutical and biotechnology experience
- Federal complex litigation and MDL experience
Keke Feng brings a background that is unusual in plaintiff pharmaceutical litigation: prior in-house counsel experience at a multinational pharmaceutical company and a biotechnology company, where she gained direct exposure to how drug companies evaluate safety signals, make labeling decisions, communicate product risks, and manage regulatory relationships.
That background is essential to Dupixent CTCL litigation allegations, including questions about what information was available, when safety questions were identified, and what disclosures were made in labeling and risk communications.
MedLaw Group reviews Dupixent CTCL inquiries with that regulatory and corporate context in mind, alongside federal litigation experience and MDL familiarity. We review Dupixent CTCL inquiries from individuals and families across the United States. Depending on the facts, jurisdiction, and litigation posture, matters may be reviewed or handled with appropriate counsel.
A focused review for a complex pharmaceutical issue
Dupixent CTCL inquiries often involve more than a simple medication history. They may require attention to dermatology records, oncology records, pathology findings, diagnosis timelines, drug labeling questions, and developing litigation.
MedLaw Group reviews these inquiries through a focused Dupixent CTCL lens. The purpose is to understand whether the facts suggest a potentially relevant history, including Dupixent use, a CTCL-related diagnosis, timing, progression, and available medical records.
A review process connected to Dupixent litigation counsel
MedLaw Group reviews Dupixent CTCL inquiries through a focused, personal process that looks at each person's medical history, diagnosis timeline, Dupixent use, and potential fit with the current litigation review.
When an inquiry appears to fit the CTCL-focused review, MedLaw Group works to involve attorneys in leadership or organizing roles in the Dupixent litigation early in the evaluation process. This helps ensure that potentially relevant inquiries are reviewed with litigation-specific judgment, including current case criteria, medical-record issues, diagnosis history, and the developing science.
When a matter moves forward, MedLaw Group may also remain involved as a client-facing support and coordination point. That can include helping clients understand what information may be needed, communicating about next steps, coordinating records, and supporting preparation for later stages of the case.
What may matter in a Dupixent CTCL review
CTCL-related diagnosis
Whether medical records mention CTCL, mycosis fungoides, Sézary syndrome, or another related T-cell lymphoma.
Timeline and records
Whether records may show symptom changes, delayed diagnosis, progression, pathology findings, or specialist evaluation.
Review fit
Whether the inquiry fits the current CTCL-focused review and may warrant deeper evaluation.
What happens after you submit a review request?
After a form is submitted, MedLaw Group reviews the information for initial evaluation. If the inquiry appears to fit the CTCL-focused review, MedLaw Group may coordinate further review with Dupixent litigation counsel. If follow-up is appropriate, MedLaw Group or counsel working with the Dupixent CTCL review may contact you for additional information.
Not every inquiry will qualify for further review, and no attorney-client relationship is created unless and until a written agreement is signed.
For medical and scientific context, read Dupixent & CTCL, or request an initial case review.
Last reviewed by Keke Feng, Esq. — May 2026
Frequently Asked Questions
Who reviews Dupixent CTCL inquiries submitted through this site?
MedLaw Group conducts an initial review of Dupixent CTCL inquiries. When an inquiry appears to fit the current CTCL-focused review, MedLaw Group works to involve attorneys in leadership or organizing roles in the Dupixent litigation early in the evaluation process.
Why does pharmaceutical and biotechnology experience matter in a Dupixent CTCL review?
Dupixent CTCL inquiries may involve medical science, drug labeling, regulatory context, safety communications, diagnosis history, and company conduct. Experience with pharmaceutical and biotechnology legal issues can help frame the questions that matter during early review.
What medical history may matter in a Dupixent CTCL inquiry?
Important information may include when Dupixent was used, what diagnosis was made, whether records mention CTCL, mycosis fungoides, Sézary syndrome, or another related T-cell lymphoma, when symptoms changed, and whether pathology, dermatology, oncology, or specialist records are available.
What role can MedLaw Group play in a Dupixent CTCL matter?
MedLaw Group may serve as a client-facing review, coordination, and support point for Dupixent CTCL inquiries and matters. If an inquiry appears to fit the current review focus, MedLaw Group may coordinate with Dupixent litigation counsel, including attorneys in leadership or organizing roles in the litigation. Depending on the matter, MedLaw Group may remain involved beyond the initial review, including helping with client communication, document collection, case coordination, and preparation for later litigation stages. The specific role of MedLaw Group and any litigation counsel is determined case by case, and submitting information does not mean any attorney has agreed to represent you.
Do I need all of my medical records before submitting a review request?
No. You can begin with basic information about Dupixent use, diagnosis history, and timeline. Additional records may be requested later if the inquiry appears to warrant further review.
Does submitting a form create an attorney-client relationship?
No. Submitting information requests an initial review only. It does not create an attorney-client relationship and does not mean your matter has been accepted.
Start Free Case Review
If you used Dupixent and were later diagnosed with CTCL or another related T-cell lymphoma, you may submit basic information for a focused initial review. You do not need to have every record ready before starting.